1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Aldrich Syndrome in 1 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Miki, H | 1 |
Nonoyama, S | 1 |
Zhu, Q | 1 |
Aruffo, A | 1 |
Ochs, HD | 1 |
Takenawa, T | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
[NCT00004341] | 0 participants | Observational | 1995-07-31 | Active, not recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 other study available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Aldrich Syndrome
Article | Year |
---|---|
Tyrosine kinase signaling regulates Wiskott-Aldrich syndrome protein function, which is essential for megakaryocyte differentiation.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amino Acid Sequence; Animals; Antibodies; Benzoquinon | 1997 |